Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
BMJ Open|December 8, 2018
PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trialMiles Parkes, Nurulamin M Noor, Francis Dowling, et al.
BMJ Open|September 19, 2018
Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trialTian Xiao Zhao, Michalis Kostapanos, Charmaine Griffiths, et al.
BMJ Open|May 11, 2018
Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trialRagada El-Damanawi, Michael Lee, Tess Harris, et al.
The Lancet. Respiratory Medicine|November 17, 2023
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trialFrances C Hall, Joseph Cheriyan, Andrew P Cope, et al.
The New England Journal of Medicine|November 2, 2017
ACE Inhibitors and Statins in Adolescents with Type 1 DiabetesM Loredana Marcovecchio, Scott T Chiesa, Simon Bond, et al.
BMJ Open|October 7, 2022
Low-dose <i>i</i>nterleukin 2 for the reduction of <i>v</i>ascular inflammati<i>o</i>n in acute corona<i>ry</i> syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trialRouchelle Sriranjan, Tian Xiao Zhao, Jason Tarkin, et al.
JCI Insight|October 5, 2018
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetesEleonora Seelig, James Howlett, Linsey Porter, et al.
The Lancet. Neurology|December 13, 2025
Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trialJulia C Greenland, Kerry Dresser, Emma Cutting, et al.
BMJ (Clinical Research Ed.)|May 16, 2022
Visualising harms in publications of randomised controlled trials: consensus and recommendationsRachel Phillips, Suzie Cro, Graham Wheeler, et al.
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Pageof 6